Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Proventil HFA and ventolin have similar safety profiles during regular use.

Tinkelman DG, Bleecker ER, Ramsdell J, Ekholm BP, Klinger NM, Colice GL, Slade HB.

Chest. 1998 Feb;113(2):290-6.

PMID:
9498941
2.

Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics.

Bleecker ER, Tinkelman DG, Ramsdell J, Ekholm BP, Klinger NM, Colice GL, Slade HB.

Chest. 1998 Feb;113(2):283-9.

PMID:
9498940
3.

Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin.

Dockhorn RJ, Wagner DE, Burgess GL, Hafner KB, Letourneau K, Colice GL, Klinger NM.

Ann Allergy Asthma Immunol. 1997 Jul;79(1):85-8.

PMID:
9236507
4.

Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma.

Lumry W, Noveck R, Weinstein S, Barnhart F, Vandermeer A, Murray A, Reisner C.

Ann Allergy Asthma Immunol. 2001 Mar;86(3):297-303.

PMID:
11289328
6.
7.

Safety of long-term treatment with HFA albuterol.

Ramsdell JW, Klinger NM, Ekholm BP, Colice GL.

Chest. 1999 Apr;115(4):945-51.

PMID:
10208190
8.

Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma.

Shapiro G, Bronsky E, Murray A, Barnhart F, VanderMeer A, Reisner C.

Arch Pediatr Adolesc Med. 2000 Dec;154(12):1219-25.

PMID:
11115306
9.

A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.

Langley SJ, Sykes AP, Batty EP, Masterson CM, Woodcock A.

Ann Allergy Asthma Immunol. 2002 May;88(5):488-93.

PMID:
12027070
10.

Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.

Baumgarten CR, Dorow P, Weber HH, Gebhardt R, Kettner J, Sykes AP.

Respir Med. 2000 Jun;94 Suppl B:S17-21.

PMID:
10919681
13.

A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects.

Tripp K, McVicar WK, Nair P, Corren J, Pleskow WW, Goodwin E, Baumgartner RA, Hanrahan JP.

J Allergy Clin Immunol. 2008 Sep;122(3):544-9. doi: 10.1016/j.jaci.2008.06.015. Epub 2008 Aug 9.

PMID:
18692886
15.

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.

FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, Brambilla R.

J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):427-35.

PMID:
10069876
18.
20.

Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.

Bronsky E, Ekholm BP, Klinger NM, Colice GL.

J Asthma. 1999;36(1):107-14.

PMID:
10077140

Supplemental Content

Support Center